Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
NCT02691182 · Supernus Pharmaceuticals, Inc. · PHASE3 · terminated · last registry update 2024-05-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The program was shut down due to a lack of efficacy.” | – | Registry record, Supernus Pharmaceuticals, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DRD2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-04-01Phase 3 first posted: Wake Forest University Health Sciences, Magnesium + Placebo (NCT06904287)
- 2024-11-29Also stopped (withdrawn): Corewell Health South, Ketorolac + Acetaminophen (NCT03472872)
- 2024-11-20Results posted on the registry: Christine Oryhan, Opioid Anesthetics + Non Opioid Analgesics (NCT04081545)
- 2024-10-01Results posted on the registry: Wake Forest University Health Sciences, Magnesium Sulfate + Metoclopramide 10mg (NCT05967442)
- 2024-09-19Results posted on the registry: National Cancer Institute (NCI), Cediranib + Sunitinib (NCT01391962)
- 2024-09-19Results posted on the registry: Elizabeth Berry-Kravis, 5-Hydroxytryptophan + Ergoloid Mesylates (NCT05030129)
- 2024-08-07Also stopped (withdrawn): Australasian Leukaemia and Lymphoma Group, Standard anti-emetics in conjunction with R-CHOP (NCT01843868)
- 2024-08-01Also stopped (terminated): Christian Fromm, MD, Paracervical injection + prochlorperazine and diphenhydramine.(Standard Treatment) (NCT04109885)
- 2024-06-06Results posted on the registry: University Medical Center of Southern Nevada, Normal Saline 5mL + Normal Saline 20mL/kg (NCT03185130)
- 2024-05-08Results posted on the registry: National Cancer Institute (NCI), TRC102 (NCT01851369)
- 2024-04-17Phase 3 first posted: State University of New York - Upstate Medical University, Dexmedetomidine + Lorazepam (NCT06370442)
- 2024-04-02Also stopped (withdrawn): Koen van Besien, Evomela + Prochlorperazine (NCT05013437)
- 2024-03-18Results posted on the registry: Supernus Pharmaceuticals, Inc., SPN-810 (18 mg) + SPN-810 (36 mg) (NCT02618434)
- 2024-03-04Results posted on the registry: Mike O'Callaghan Military Hospital, Compazine + Ketamine (NCT02735343)
- 2024-03-04Also stopped (terminated): Mike O'Callaghan Military Hospital, Compazine + Ketamine (NCT02735343)
- 2024-02-14Results posted on the registry: Stony Brook University, Aprepitant 80 mg Oral Capsule + scopolamine transdermal (NCT03435003)
- 2023-12-13Phase 3 first posted: Ain Shams University, Haloperidol Injection (NCT06168773)
- 2023-11-18Results posted on the registry: InterveXion Therapeutics, LLC, IXT-m200 + Lorazepam (NCT04715230)
- 2023-11-18Also stopped (terminated): InterveXion Therapeutics, LLC, IXT-m200 + Lorazepam (NCT04715230)
- 2023-08-18Results posted on the registry: Ferring Pharmaceuticals, Quinagolide 360 µg + Quinagolide 720 µg (NCT03692403)
- 2023-08-01Phase 3 first posted: Wake Forest University Health Sciences, Magnesium Sulfate + Metoclopramide 10mg (NCT05967442)
- 2023-06-09Phase 3 first posted: Christian Hassager, Dexamethasone + Olanzapine (NCT05895838)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision